Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prostate Cancer Program (ViferaXS)
- Development stage
- Unknown
- Lead developer
- ViferaXS
- Modality
- Cell Therapies, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
The ViferaXS Prostate Cancer Program is an investigational immunotherapy that utilizes an off-the-shelf cell therapy in combination with a bispecific T-cell engager approach. This therapeutic strategy is designed to target three specific antigens frequently overexpressed in prostate cancer: Tenascin-C (specifically the 3C splice variant, TN3C), Prostate Stem Cell Antigen (PSCA), and Six-Transmembrane Epithelial Antigen of the Prostate 1 (STEAP1). By employing a bispecific combination, the therapy aims to recruit and activate T cells to recognize and eliminate tumor cells expressing these markers. The program is currently being evaluated in Phase 1/2 clinical trials for the treatment of prostate cancer.
- Other names
- ViferaXS-TN3C-PSCA-STEAP1-off-the-shelf cell therapy-bispecific combination-Prostate CancerViferaXS-TN-3C-PSCA-STEAP1-off-the-shelf cell therapy-bispecific combination-Prostate CancerViferaXS-TN 3C-PSCA-STEAP1-off-the-shelf cell therapy-bispecific combination-Prostate Cancer
Beyond the preview
Go deeper on Prostate Cancer Program (ViferaXS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prostate Cancer Program (ViferaXS).